CN Patent

CN105566225A — 一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法

Assigned to Crystal Pharmatech Co Ltd · Expires 2016-05-11 · 10y expired

What this patent protects

一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法。本发明涉及一种治疗黑色素瘤和卵巢癌的晶型及其制备方法。本发明提供的晶型Α和晶型Β稳定性好，工艺提纯效果显著，且溶解度、引湿性符合药用要求。该晶型制备方法简单，成本低廉，对未来该药物的优化和开发具有重要价值。

USPTO Abstract

一种口服丝裂原活化蛋白激酶抑制剂的晶型及其制备方法。本发明涉及一种治疗黑色素瘤和卵巢癌的晶型及其制备方法。本发明提供的晶型Α和晶型Β稳定性好，工艺提纯效果显著，且溶解度、引湿性符合药用要求。该晶型制备方法简单，成本低廉，对未来该药物的优化和开发具有重要价值。

Drugs covered by this patent

Patent Metadata

Patent number
CN105566225A
Jurisdiction
CN
Classification
—
Expires
2016-05-11
Drug substance claim
No
Drug product claim
No
Assignee
Crystal Pharmatech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.